Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

This publication has 23 references indexed in Scilit:

• Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia
  European Urology, 2000
• Preclinical Pharmacology of α1-Adrenoceptor Antagonists
  European Urology, 1999
• A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
  European Urology, 1999
• Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice
  Prostate Cancer and Prostatic Diseases, 1998
• Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
  European Urology, 1998
• Clinical uroselectivity: evidence from patients treated with slow‐release alfuzosin for symptomatic benign prostatic obstruction
  British Journal of Urology, 1997
• Efficacy and Safety of Sustained- Release Alfuzosin 5 mg in Patients with Benign Prostatic Hyperplasia
  European Urology, 1997
• Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?
  Published by Wolters Kluwer Health ,1995
• Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin
  British Journal of Urology, 1992
• Alfuzosin for treatment of benign prostatic hypertrophy
  The Lancet, 1991